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Letter to the Editor 
 
Association of a TNFSF13B (BAFF) 
regulatory region single nucleotide 
polymorphism with response to rit- 
uximab in antineutrophil cytoplas- 
mic antibody–associated vasculitis 
 
To the Editor: 
Rituximab is effective at inducing and maintaining remission in 
antineutrophil cytoplasmic antibody (ANCA)-associated vascu- 
litis (AAV).1,2 The wide interpatient variability in the duration of 
B-cell depletion and time to relapse as well as the significant 
relapse risk after treatment, costs, and adverse event rates neces- 
sitate improved patient stratification.3 
Several biomarkers have been explored
4,5 
in diseases treated 
with rituximab; however, all require validation before they can 
enter clinical practice; among them, a role for candidate single 
nucleotide polymorphisms (SNPs) has been proposed.
6 
However, 
no SNP has so far shown a reliable association with response to 
treatment and no such study has been performed in AAV. We 
tested a panel of candidate SNPs to investigate their potential as- 
sociation with response to rituximab in 2 large cohorts of patients 
with AAV. 
We included patients with granulomatosis with polyangiitis 
(GPA, Wegener’s) and microscopic polyangiitis (MPA) who 
received rituximab mainly for relapsing or refractory disease. 
We aimed at identifying associations between the tested SNPs and 
the rate of rituximab failure at 6 months and time to rituximab 
failure (relapse). For further details, see the Methods section in 
this article’s Online Repository at www.jacionline.org. 
We enrolled 213 patients in the primary and 109 in the 
replication cohort (see Table E1 in this article’s Online Repository 
at www.jacionline.org). Across the primary cohort, a mean of 
0.88 6 0.19 SNPs per sample could not be called and no SNP 
had  a  P value  of  less  than  .05  for  departure  from  Hardy- 
Weinberg Equilibrium (HWE) (see Table E2 in this article’s On- 
line Repository at www.jacionline.org). 
In the primary cohort, the TNFSF13B SNP rs3759467 was 
associated with time to rituximab failure (P 5 2.86 3 10204, 
Pcorr 5 .01) (Fig 1, A; see Table E3 in this article’s Online Repos- 
itory at www.jacionline.org). We genotyped this SNP in the repli- 
cation cohort (test for deviation from HWE P 5 .7627; rate of 
missing calls, 3%) where the association with time to rituximab 
failure was confirmed (P 5 .002) (Fig 1, B). 
Because the results suggested a recessive effect for the SNP 
rs3759467, we used recessive models for the analysis in the 
replication cohort and reanalysis of the primary cohort. Meta- 
analyses of the 2 cohorts confirmed an association between the 
TNFSF13B SNP rs3759467 and the 2 end points (P 5 .0065 and 
8.5 3 10206, respectively) (Table I). 
We then compared the main clinical characteristics of the 
carriers of the CC genotype with the carriers of the TC and TT 
genotypes (see Table E4 in this article’s Online Repository at 
www.jacionline.org) and found a higher rate of detectable periph- 
eral B cells 6 months after rituximab in carriers of the CC geno- 
type (50% vs 14%; P 5 .0146) as well as a smaller reduction in 
IgM levels (1.5 [1.4-10.92] and 1 [1-1.33]; P 5 .01539). 
The haplotype analyses of the 59 regulatory region of the 
TNFSF13B gene based on the genotyped SNPs confirmed an 
association of the risk of rituximab failure at 6 months for the 
haplotype including the risk allele of the SNP rs3759467 (see 
Table E5 in this article’s Online Repository at www.jacionline. 
org). 
In view of the small number of MPO-ANCA–positive patients 
and the fact that all the minor homozygous carriers for the 
rs3759467 SNP were PR3-ANCA positive, we reanalyzed the 
primary cohort according to ANCA specificity (see Table E6 in 
this article’s Online Repository at www.jacionline.org); the asso- 
ciation with the B-cell activating factor (BAFF) SNP rs3759467 
was limited to the PR3-ANCA subgroup (see Tables E6 and E7 
in this article’s Online Repository at www.jacionline.org). 
In the MPO-ANCA subgroup, a different association 
emerged in the primary cohort with the SNP rs6822844 in the 
IL2-IL21 area (rituximab failure risk at 6 months and time to 
rituximab  failure,  P  5  4.2  3  10204    –  Pcorr    5 .03  and 
P 5 1.9 3 10204 – Pcorr 5 .0068, respectively) (Table E6). 
However, this was not replicated (rituximab failure risk at 
6 months and time to rituximab failure, P 5 .153 and .172, 
respectively) in the context of a small sample size (19 patients), 
although there was a trend to an increased risk of treatment failure 
at 6 months for the carriers of the T allele (see Table E8 in this 
article’s Online Repository at www.jacionline.org). 
We have identified an SNP (rs3759467) in the 59 regulatory 
region of the gene TNFSF13B (BAFF) able to predict response to 
rituximab in 2 cohorts of patients with AAV. Interestingly, the car- 
riers of the unfavorable genotype showed in addition to a poor 
response to rituximab, a higher proportion of detectable B cells 
6 months after infusion and a smaller reduction in IgM levels. 
A BAFF level increase after rituximab treatment has been 
described and a central role for this cytokine in AAV pathogenesis 
has also been proposed.7 The 59 regulatory region of the BAFF 
gene includes several SNPs that may have a modulatory effect; 
the -TTTT- haplotype of this region has been associated with 
BAFF levels8 and response to rituximab in rheumatoid arthritis.6 
In our study, a trend toward better response in carriers of this 
haplotype was also observed. 
The role of the SNP rs3759467 will need to be clarified; this is 
part of a TAAT- binding site; the lack of a heterozygous effect may 
suggest that the losing of both sites is required to obtain the 
phenotype causing poor response. It seems likely that this SNP 
modulates B-cell survival and/or activity; this might be a 
consequence of higher baseline BAFF levels or greater BAFF 
increases after a B-cell–depleting event. 
Interestingly, our findings were restricted to the subgroup of 
patients  with  positive  PR3-ANCA  probably  due  to  power 
limitations in the MPO-ANCA subgroup where the reanalyses 
identified a different association in the IL2-IL21 area, as already 
described in systemic lupus erythematosus.
9
 
Our study has limitations: a sample size relatively small for a 
genetic study and the retrospective nature of data collection may 
be weaknesses; however, at the time of this writing, it would not 
have been possible to enroll a comparable prospective cohort. We 
also have to acknowledge the closeness of the P value for the 
departure from HWE for the SNP rs3759467 in the primary 
cohort; however, the replication of the data in the context of a 
P value for the departure  from  HWE  far  from  significance 
(P 5 .7627) is reassuring on the reliability of the overall finding. 
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FIG 1. Rituximab (RTX) failure-free survival in an exploratory cohort of 213 patients (A) and in a replication 
cohort of 109 patients (B) stratified according to the genotypes of the SNP rs3759467 of the gene TNFSF13B. 
 
 
TABLE I. Association results for the SNP rs3759467 after fixed- 
effects weighted meta-analysis for the 2 main outcomes assessed 
in our study assuming a recessive model 
Replication 
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Outcome     Primary  cohor t 
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Zdenka Hruskova, PhDn 
 ass essed OR-HR P  value OR-HR    P  value    OR-HR P   value   Maria C. Cid, PhDo 
Rituximab 
failure risk 
at 6 mo 
Time to 
rituximab 
failure 
9.1 .06489 8.6 .008996 8.8 .0065 
 
 
12.4    7 3 10204      5.39    .0024 7.3 8.5 3 10206 
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In conclusion, we have identified a TNFSF13B (BAFF) SNP 
(rs3759467) associated with response to rituximab in 2 
independent cohorts of patients with AAV. This SNP may be 
useful in identifying patients likely to respond poorly to rituximab 
and for whom alternative treatments should be considered. 
Further studies are required to confirm this finding and to clarify 
its mechanism of action. 
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METHODS 
Eligibility  criteria  were  a  clinical  diagnosis  of  granulomatosis  with 
polyangiitis (GPA, Wegener’s) or microscopic polyangiitis (MPA) defined 
according to the European Medicines Agency (EMEA) algorithmE1 and the 
administration of rituximab for either relapsing or refractory disease or 
remission induction in few patients. Patients with a clinical diagnosis of 
eosinophilic granulomatosis with polyangiitis (formerly known as Churg-
Strauss syndrome) were not included in this study. The primary cohort 
included patients enrolled at European centers with expertise in vasculitis and 
members of the European Vasculitis Genetics Consortium and/or of the 
European Vasculitis Society (Table E9); the replication cohort was enrolled 
at the Vasculitis and Lupus Clinic, Addenbrooke’s Hospital (Cambridge, 
United  Kingdom).  All   patients   gave   written   informed   consent 
before participation. Disease severity was assessed using the Disease Extent 
Index (DEI)E2; B-cell return was defined as a B-cell count of 0.01 3 109/L 
or more. 
 
Eligibility criteria 
Patients affected by GPA or MPA for whom there was indication to the 
beginning of treatment with rituximab as follows: 
d Relapsing disease: disease flare defined as a DEI score of more than 2, 
physician assessment of relapsing disease, and need for immunosuppres- 
sion escalation. 
d Refractory disease: persistent activity of disease despite treatment with 
intravenous  and/or  oral  steroids  and  other  immunosuppressive agents 
and physician assessment of refractory disease for at least 3 months. 
d Other indications: 
B First presentation of the disease. 
B Contraindication to standard treatment (eg, recurrent infection and 
fertility preservation). 
B Grumbling disease: low-grade disease activity according to physician 
assessment that is not formally fulfilling the inclusion criteria in terms 
of disease activity scoring. 
B Patients unable to taper the prednisolone below 15 mg/d on their 
previous therapeutic regimen. 
B Need for steroid-free regimen. 
 
End points 
The end points of the study were to identify associations between the 
tested SNPs and the rate of rituximab failure at 6 months and time to 
rituximab failure (relapse) within 12 months of the first rituximab 
administration. We defined rituximab failure as active vasculitis requiring 
escalation of immunosuppressive treatment. SNPs showing an association 
with at least 1 of the 2 end points in the primary cohort were analyzed in 
the replication cohort for confirmation and then meta-analyses of the 
results were performed. Subgroup analyses were performed after merging 
the 2 cohorts. 
 
Genotyping 
Eighteen candidate SNPs were chosen according to a biological rationale or 
previous reports (Table E2).E3-E8 DNA was extracted from peripheral blood 
using the Qiagen DNA extraction kit; genotyping was performed using 
TaqMan and Sequenom platforms with the exception of the FCGR2B SNP 
rs1050501, which was genotyped via a ‘‘modified’’ TaqMan approach as 
previously described.E9 
Statistics 
Statistical analysis was performed using the software R (http://www.r- 
project.org) and the packages coin,E10 survival,E11 SNPassoc,E12 and 
hapassoc.E13 
For exploratory purposes, the primary cohort has been analyzed using the 
Cochrane-Armitage test with log-additive model. As a result of the 
exploratory analysis (recessive mechanism for the SNP rs3759467), the 
replication cohort has been analyzed immediately using a recessive model of 
the same test. We have then reanalyzed the primary cohort with the same 
model and a meta-analysis has been performed. 
The time to rituximab failure has been assessed by Kaplan-Meier survival 
analysis and a log-rank test has been used to compare populations. Cox- 
proportional hazards regression model has been used for reanalyses of the 
time to rituximab failure in the primary and replication cohort using a 
recessive model and the results have been used for meta-analyses for this 
end point. 
Delta of reduction of IgG and IgM levels has been assessed as the ratio 
between the baseline value and the value at the time point of interest. 
Results are expressed as value and percentage for categorical variables and 
median and interquartile range or mean and SEM for continuous variables 
when appropriate. 
In view of the observation of an association in the 59 regulatory region of the 
gene TNFSF13B, we decided to study the haplotypes of this region because 4 
of the SNPs included in the study were in strong linkage disequilibrium and 
organized in well-renowned haplotype blocks. We used the R package hapas- 
socE13 for the identification of the haplotypes and the Cochrane-Armitage test 
to explore association between haplotypes and the risk of treatment failure 
6 months after treatment with rituximab. 
Meta-analyses were performed via a fixed-effects weighted method using the 
Linux version of the software metal (http://csg.sph.umich.edu/abecasis/Metal/ 
download/). Bonferroni corrections for multiple testing were performed, with 
corrected P (Pcorr) values of less than .05 considered significant. 
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TABLE E1. Patients’ characteristics 
 
 
Characteristic 
 
 
Primary 
cohort 
(n 5 213) 
 
 
Replication 
cohort 
(n 5 109) 
 
Age (y) 53.3 (40.2-64.7) 57.1 (41.9-65) 
Sex: male 111 (52) 48 (44) 
Diagnosis 
GPA 185 (87) 94 (86) 
MPA 29 (13) 15 (14) 
ANCA specificity 
PR3 148 (70) 78 (72) 
MPO 29 (13) 19 (17) 
Negative 36 (17) 12 (11) 
Prior disease duration (mo) 56.3 (12.8-113.8) 48.2 (16.5-138) 
Indication for rituximab 
Relapse 108 (51) 53 (49) 
Refractory disease 76 (36) 15 (14) 
Other* 26 (13) 41 (38) 
Rituximab dose for induction regimen 
375 mg/m2  weekly for 4 wk 68 (32) 28 (26) 
1 g 2 wk apart 143 (67) 79 (72) 
Othert 2 (1) 2 (2) 
No. of previous immunosuppressive 
agents 
2 (1-3) 3 (2-3) 
Cyclophosphamide 175 (82) 94 (86) 
Cumulative dose (g) 10 (4-28) 10 (4-27) 
Methotrexate 92 (43) 28 (26) 
Azathioprine 91 (42) 76 (70) 
MMF 49 (23) 60 (55) 
Immunosuppression at study entryt 1 (0-1) 1 (0-1) 
Cyclophosphamide 35 (16) 15 (14) 
Methotrexate 30 (14) 8 (7) 
MMF 18 (9) 17 (16) 
Azathioprine 14 (8) 11 (10) 
IV methylprednisolone 8 (4) 17 (16) 
Oral prednisolone dose 25 mg (12.5-50) 12.5 mg (10-20) 
Organ involvement at study entry 
ENT 132 (62) 60 (46) 
Lungs 88 (41) 21 (19) 
Joints 83 (39) 26 (24) 
Kidneys 82 (39) 24 (22) 
Eye 59 (28) 12 (11) 
Peripheral nervous system 25 (12) 9 (8) 
Central nervous system 11 (5) 3 (3) 
Gastrointestinal 4 (2) 0 (0) 
Cardiac 4 (2) 0 (0) 
DEI 5 (3.75-7) 3 (2-5) 
ANCA status at study entry 
Positive by ELISA 174 (82) 73 (67) 
PR3 148 (70) 59 (54) 
MPO 26 (12) 14 (13) 
Negative 39 (18) 36 (33) 
 
Results are expressed as n/N (%) or median (IQR) when appropriate. 
ENT, Ear, nose and throat; IV, intravenous; MMF, mycophenolate mofetil. 
*Other. Includes first presentation of disease, contraindication to standard treatment, 
grumbling disease, patients unable to taper the prednisolone dose, need for steroid-free 
regimen. 
tOther. Includes 500 mg 2 weeks apart (2 cases), administration of a single dose of 1 g 
of rituximab (1 case), administration of 3 doses of rituximab at the dose of 375 mg/m2. 
tExcluding oral steroids, but including oral immunosuppressive agents continued for 
at least 3 months after the administration of the first rituximab dose. 
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TABLE E2. SNPs tested, minor allele frequency (MAF) observed, 
and test for deviation from HWE in the primary cohort of 213 
patients with AAVs treated with rituximab 
SNP Alleles Gene MAF HWE-P 
 
rs396991 G/T FCGR3A 0.439 0.407 
rs1050501 T/C FCGR2B 0.11 0.716 
rs1224141 G/T TNFSF13B 0.235 0.839 
rs16972216 A/G TNFSF13B 0.173 1.000 
rs1224147 T/C TNFSF13B 0.221 0.680 
rs10508198 C/G TNFSF13B 0.339 0.058 
rs12583006 A/T TNFSF13B 0.231 0.554 
rs8181791 A/G TNFSF13B 0.307 0.327 
rs172378 A/G C1QA 0.38 0.303 
rs9514828 C/T TNFSF13B 0.442 0.888 
rs1801274 C/T FCGR2A 0.495 0.407 
rs1800795 C/G IL6 0.359 0.881 
rs6822844 G/T IL2-IL21 0.127 0.542 
rs3759467 T/C TNFSF13B 0.172 0.057 
rs28362491 DEL/ATTG NFKB1 0.383 0.102 
rs1800471 C/G TGFB1 0.09 1.000 
rs1041569 A/T TNFSF13B 0.166 1.000 
rs9514827 T/C TNFSF13B 0.318 0.626 
The test for deviation from HWE has been calculated using the R package 
SNPasso,E12 and threshold for significance has been established to P < .05. 
MAF, Minor allele frequency. 
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TABLE E3. Association of 18 candidate SNPs with the 2 main 
outcomes explored in the study: Rituximab failure risk at 
6 months and time to rituximab failure 
 
Rituximab 
failure risk at 
6 mo 
Time to rituximab 
failure 
 
SNP Alleles Gene P value Pcorr P value Pcorr 
rs396991 G/T FCGR3A .275 1 .495 1 
rs1050501 T/C FCGR2B .399 1 .089 1 
rs1224141 G/T TNFSF13B .006* 0.216 .268 1 
rs16972216 A/G TNFSF13B .328 1 .521 1 
rs1224147 T/C TNFSF13B .01* 0.36 .366 1 
rs10508198 C/G TNFSF13B .295 1 .083 1 
rs12583006 A/T TNFSF13B .625 1 .129 1 
rs8181791 A/G TNFSF13B .489 1 .968 1 
rs172378 A/G C1QA .987 1 .441 1 
rs9514828 C/T TNFSF13B .854 1 .943 1 
rs1801274 C/T FCGR2A .949 1 .605 1 
rs1800795 C/G IL6 .574 1 .735 1 
rs6822844 G/T IL2-IL21 .184 1 .853 1 
rs3759467 A/G TNFSF13B .911 1 2.86 3 10204* 0.01* 
rs28362491 -/ATTG NFKB1 .012* 0.432 .245 1 
rs1800471 C/G TGFB1 .727 1 .978 1 
rs1041569 A/T TNFSF13B .461 1 .88 1 
rs9514827 T/C TNFSF13B .577 1 .825 1 
Pcorr, P corrected for multiple testing according to Bonferroni. 
*Statistically significant. 
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TABLE E4. Main clinical characteristics of patients at time of study entry and 6 months after rituximab according to the different 
genotype for the SNP rs3759467 of the gene TNFSF13B in the overall study population (primary 1 replication cohorts merged) 
Characteristic Genotype TT 1 TC Genotype CC P value 
 
Diagnosis (GPA) 260 of 301 (86%) 7 of 7 (100%) .2951 
Historical ANCA specificity (PR3) 209 of 294 (71%) 7 of 7 (100%) .2453 
DEI 4 (2-6) 4 (3.5-4.5) .6925 
Age (y) 54.2 (40.8-65) 54.8 (37.5-58.5) .5965 
Indication for rituximab (active flare)* 233 of 299 (78%) 6 of 7 (86%) .6229 
B-cell return at 6 mo 
ANCA positivity at 6 mo 
22 of 161 (14%) 
137 of 244 (56%) 
3 of 6 (50%) 
6 of 7 (86%) 
.0146t 
.12 
IgG delta at 6 mot 1.06 (0.96-1.34) 0.97 (0.76-0.97) .09389 
IgM delta at 6 mot 1.5 (1.04-10.92) 1 (1-1.33) .01539t 
DEI score at rituximab failure 4 (2-5) 4 (2.5-4.75) .703 
Results are expressed as n/N (%) or median (IQR) when appropriate. 
B-cell return has been defined as B-cell count >_ 0.01 3 109/L. 
*Active flare defined as rituximab given either for relapsing or for refractory disease. 
tStatistically significant. 
tDelta has been calculated as the ratio between the value at the time of rituximab administration and the value at the time point of interest. Associations have been tested using the 
Mann-Whitney rank sum test. 
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TABLE E5. Haplotypes of the 59 regulatory region of the gene 
TNFSF13B and their association with risk of TF 6 months after 
treatment with rituximab according to a log-additive and 
recessive models 
Rituximab failure risk at 6 mo 
Log-additive 
model Recessive model 
 
Haplotype Frequency P value Pcorr  P value Pcorr 
TTAC 34% .635 1  .58 1 
CTAT 31% .73 1  .699 1 
TCAC 18% .028* 0.28  2.6 3 10
205* 2.6 3 10204* 
TTTT 13% .028* 0.28  .386 1 
Pooled 4% .475 1  .741 1 
 
*Statistically significant. 
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TABLE E6. Association of 18 candidate SNPs with the 2 outcomes explored in our study (rituximab failure risk at 6 months and time to 
rituximab failure) according to the historical ANCA specificity 
PR3 – AAVs (n 5 148) MPO – AAVs (n 5 29) 
Rituximab fail- 
ure 6/12 Time to rituximab failure Rituximab failure 6/12 Time to rituximab failure 
 
SNP Alleles Gene P value Pcorr  P value Pcorr  P value Pcorr  P value Pcorr 
rs396991 G/T FCGR3A .150 1  .815 1  .388 1  .25 1 
rs1050501 T/C FCGR2B .073 1  .401 1  .433 1  .808 1 
rs1224141 G/T TNFSF13B .007 0.53  .208 1  .380 1  .672 1 
rs16972216 A/G TNFSF13B .164 1  .806 1  .667 1  .705 1 
rs1224147 T/C TNFSF13B .012 0.84  .253 1  .360 1  .675 1 
rs10508198 C/G TNFSF13B .775 1  .206 1  .546 1  .824 1 
rs12583006 A/T TNFSF13B .980 1  .162 1  .966 1  .702 1 
rs8181791 A/G TNFSF13B .645 1  .829 1  .625 1  .603 1 
rs172378 A/G C1QA .733 1  .481 1  .551 1  .671 1 
rs9514828 C/T TNFSF13B .390 1  .533 1  .434 1  .782 1 
rs1801274 C/T FCGR2A 1 1  .401 1  .194 1  .562 1 
rs1800795 C/G IL6 .574 1  .392 1  .135 1  .287 1 
rs6822844 G/T IL2-IL21 .987 1  .874 1  4.2 3 10
204* 0.03*  1.9 3 10
204* 0.0068* 
rs3759467 A/G TNFSF13B .667 1  4.8 3 10
204* 0.017*  .452 1  .825 1 
rs28362491 -/ATTG NFKB1 .044 1  .263 1  .212 1  .268 1 
rs1800471 C/G TGFB1 .609 1  .148 1  .626 1  .363 1 
rs1041569 A/T TNFSF13B .306 1  .648 1  .899 1  .668 1 
rs9514827 T/C TNFSF13B .111 1  .598 1  .706 1  .534 1 
Rituximab failure rates at 6 mo were compared using a Cochrane-Armitage test with log-additive model and time to rituximab failure using log-rank test. 
*Statistically significant. 
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TABLE E7. Association results for the SNP rs3759467 in the 
subgroup of patients with PR3-ANCA after fixed-effects weighted 
meta-analysis for the 2 outcomes assessed in our study assuming 
a recessive model for the SNP 
Primary 
cohort 
(n 5 148) 
Replication 
cohort 
(n 5 78) Meta-analysis 
Outcome assessed 
 
Rituximab failure risk 
at 6 mo 
OR/HR P value OR/HR P value OR/HR P value 
 
8.2 .0853 9.2 .0089 8.8 .007 
Time to RTX-failure     11.6    .0012     6.2     .002       8.2    8.7 3 10206 
 
Rituximab failure risk at 6 months has been explored using a recessive model of the 
Cochrane-Armitage test. Time to rituximab failure has been explored using a recessive 
model of Cox-proportion hazards regression model. 
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TABLE E8. Genotype distribution for the SNP rs6822844 of the 
gene IL2-IL21 in the subgroup of patients MPO-ANCA positive of 
the replication cohort 
 
 
Genotype rs6822844 
Response at 6 mo 
Positive response TF TF percentage 
 
GG 15 1 6% 
GT 2 1 33% 
TT 0 0 0% 
 
The difference is not statistically significant (P 5 .1722, Cochrane-Armitage test, log- 
additive model) although there was a trend toward an increased risk of TF in the 
carriers of the T allele in small sample size (19 patients). 
TF, Rituximab failure. 
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TABLE E9. Primary cohort recruitment according to country 
 
Country No. of patients 
Germany 53 
Italy 49 
Sweden 46 
Denmark 41 
Czech Republic 13 
Spain 11 
 
